AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

AstraZeneca and Moderna Therapeutics announce exclusive agreement to develop pioneering messenger RNA Therapeutics™ in cardiometabolic diseases and cancer

March 21, 2013

 

AstraZeneca today announced an exclusive agreement with Moderna Therapeutics to discover, develop and commercialise pioneering messenger RNA therapeutics™ for the treatment of serious cardiovascular, metabolic and renal diseases as well as cancer. Messenger RNA therapeutics™ are an entirely new treatment approach that enables the body to produce therapeutic protein in vivo, opening up new treatment options for a wide range of diseases that cannot be addressed today using existing technologies.

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

Flagship Ventures and Merck Research Labs Form Strategic Collaboration to Foster Early-Stage Life Sciences Innovation

April 10, 2012

Initiative combines Merck’s drug development expertise with Flagship’s experience in building early stage companies

Oasys Water Continues Growth and Commercialization Momentum in Global Markets

Oasys Water Continues Growth and Commercialization Momentum in Global Markets

September 2, 2014

BOSTON--(BUSINESS WIRE)--Oasys Water, a world leader in innovative solutions for water treatment and desalination, today announced its first international commercial application underscoring successful partnership development efforts in the Chinese market. The Changxing Power Plant, located in China’s northern Zhejiang province, will use Oasys Water’s patented technology to treat the coal-fired power plant’s wastewater from flue gas desulfurization (FGD).

Joule to Host Strategic Seminar on Climate Change in Norway, Featuring Jeffrey Sachs

Joule to Host Strategic Seminar on Climate Change in Norway, Featuring Jeffrey Sachs

August 28, 2014

Bedford, MA - Joule, the innovator of a CO2 -to-fuels reverse combustion process, will convene industry and political leaders for a seminar in Oslo, Norway: “Converting Words to Action on Climate Change: The Role of Technology.” The event will be headlined by Professor Jeffrey Sachs, senior United Nations advisor and director of the Sustainable Development Solutions Network (SDSN).

Seres Health to Present Clinical Findings at ICAAC 2014 Conference

Seres Health to Present Clinical Findings at ICAAC 2014 Conference

August 28, 2014

CAMBRIDGE, Mass., Aug. 28, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, announced today that Dr.

Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration

Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration

August 26, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder.

Flagship Ventures Appoints Agricultural Industry Leader Robert Berendes as Venture Partner

Flagship Ventures Appoints Agricultural Industry Leader Robert Berendes as Venture Partner

August 25, 2014

CAMBRIDGE, Mass., Aug. 25, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, today announced the appointment of Dr. Robert Berendes as a Venture Partner. Dr. Berendes, who most recently was a member of the executive team at Syngenta, will provide strategic counsel and support to the Flagship team. Through board and advisory roles, he will engage with portfolio companies focused on innovations that address sustainability in the energy, water, and agriculture/nutrition sectors.

Joule Achieves Industry First With A 100% Increase In Photosynthetic Efficiency

Joule Achieves Industry First With A 100% Increase In Photosynthetic Efficiency

August 15, 2014

Bedford, MA – August 15, 2014 – Overcoming the limitations of photosynthesis, Joule has successfully co-opted nature’s primary energy capture process at unprecedented efficiencies for direct, continuous fuel production. This includes the engineering of a photosynthetic biocatalyst able to divert 95% of fixed carbon normally converted to biomass directly to fuel, and the industry first improvement of its photon energy conversion efficiency.

Allergan Acquires LiRIS® Program from TARIS Biomedical®

Allergan Acquires LiRIS® Program from TARIS Biomedical®

August 13, 2014
  • TARIS LiRIS® Program in Phase 2 Clinical Development for the Localized Treatment of Interstitial Cystitis / Bladder Pain Syndrome
  • Acquisition Enhances Allergan’s Leadership Position in Urology and Reinforces the Company’s Commitment to Developing Innovative Treatments to Address Important Medical Needs

Seventh Sense Biosystems Closes $16 Million Series B Financing

Seventh Sense Biosystems Closes $16 Million Series B Financing

August 13, 2014

CAMBRIDGE, Mass., Aug 13, 2014 (BUSINESS WIRE) -- Seventh Sense Biosystems, Inc. (7SBio), the pioneering developer of virtually painless blood collection and diagnostic platforms, today announced a $16 million Series B financing from a syndicate of global leaders in diagnostic technologies, pharmaceuticals and clinical diagnostic laboratory services.